New genomic study compares metastatic male vs female breast cancer across all subtypes

Iván González, Medical Oncologist at Hospital Ángeles Puebla, shared a post on X about a recent paper titled “Genomic profiling and comparative analysis of male versus female metastatic breast cancer across subtypes” published in Breast Cancer Research.

Authors: Arun Kadamkulam Syriac, Nitish Singh Nandu, Allison Clark, Mehrad Tavallai, Dexter X. Jin, Ethan Sokol, Kimberly McGregor, Jeffrey S. Ross, Natalie Danziger and Jose Pablo Leone.

“New genomic study compares metastatic male breast cancer (MaBC) with female breast cancer (FBC) across all subtypes:

ER+/HER2-:
More alterations in GATA3 (26.2% vs. 15.9%), BRCA2 (13.8% vs. 5.3%), MDM2 (13.3% vs. 6.14%), CDK4 (7.1% vs. 1.8%).
Fewer mutations in TP53 (11% vs. 42.6%) and ESR1 (5.7% vs. 14.6%).

ER+/HER2+:
More variants in ERBB2 (22.7% vs. 0.6%), GATA3 (36.3% vs. 6.2%), MDM2 (36.3% vs. 4.9%). Fewer alterations in TP53 (9.1% vs. 61.7%).

Triple negatives:
Fewer alterations in TP53 (25% vs. 84.4%).

This study reveals significant genomic differences between MaBC and FBC. These differences may affect how tumors respond to treatments, suggesting that therapies should be tailored specifically for each gender to be more effective.”

Source: Iván González/X